Persistent hypomagnesemia following cisplatin chemotherapy in patients with ovarian cancer. Academic Article uri icon

Overview

abstract

  • The development of acute hypomagnesemia following cisplatin administration is a well-recognized complication associated with the use of this chemotherapeutic agent. However, there is limited information available in the medical literature concerning how long this abnormality may persist following the discontinuation of cisplatin. Of 13 patients with ovarian cancer who had a baseline serum magnesium determination obtained prior to the initiation of a second-line cisplatin-based chemotherapy regimen, 9 (69%) were found to be hypomagnesemic (serum magnesium less than 1.4 mg/l), including 3 patients with serum magnesium values less than 1.0 mequiv/l. The median cisplatin-free interval for these 9 patients was 19 months (range 6-40 months). We conclude that persistent, and possibly permanent, hypomagnesemia is common following cisplatin chemotherapy.

publication date

  • January 1, 1991

Research

keywords

  • Cisplatin
  • Magnesium
  • Ovarian Neoplasms

Identity

Scopus Document Identifier

  • 0026012121

Digital Object Identifier (DOI)

  • 10.1007/BF01613129

PubMed ID

  • 2007614

Additional Document Info

volume

  • 117

issue

  • 2